CN115261273A - 一株詹氏乳杆菌及其应用 - Google Patents
一株詹氏乳杆菌及其应用 Download PDFInfo
- Publication number
- CN115261273A CN115261273A CN202210932906.1A CN202210932906A CN115261273A CN 115261273 A CN115261273 A CN 115261273A CN 202210932906 A CN202210932906 A CN 202210932906A CN 115261273 A CN115261273 A CN 115261273A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus jensenii
- gforu
- expression
- gene
- genes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 241001561398 Lactobacillus jensenii Species 0.000 title claims abstract description 46
- 206010061218 Inflammation Diseases 0.000 claims abstract description 14
- 230000004054 inflammatory process Effects 0.000 claims abstract description 14
- 230000008591 skin barrier function Effects 0.000 claims abstract description 13
- 230000004663 cell proliferation Effects 0.000 claims abstract description 8
- 239000002537 cosmetic Substances 0.000 claims abstract description 5
- 235000013305 food Nutrition 0.000 claims abstract description 4
- 210000004027 cell Anatomy 0.000 claims description 54
- 108090000623 proteins and genes Proteins 0.000 claims description 50
- 230000014509 gene expression Effects 0.000 claims description 43
- 239000006228 supernatant Substances 0.000 claims description 34
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 25
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 24
- 210000002744 extracellular matrix Anatomy 0.000 claims description 24
- 210000003491 skin Anatomy 0.000 claims description 16
- 239000000047 product Substances 0.000 claims description 14
- 230000003712 anti-aging effect Effects 0.000 claims description 12
- 230000006907 apoptotic process Effects 0.000 claims description 12
- 239000001963 growth medium Substances 0.000 claims description 11
- 230000008439 repair process Effects 0.000 claims description 11
- 230000004888 barrier function Effects 0.000 claims description 10
- 210000002950 fibroblast Anatomy 0.000 claims description 8
- 238000009630 liquid culture Methods 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 8
- 108090001005 Interleukin-6 Proteins 0.000 claims description 6
- 230000003828 downregulation Effects 0.000 claims description 6
- 230000035755 proliferation Effects 0.000 claims description 6
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 5
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 claims description 4
- 108090001007 Interleukin-8 Proteins 0.000 claims description 4
- 101150016206 Trpv1 gene Proteins 0.000 claims description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 4
- 230000002225 anti-radical effect Effects 0.000 claims description 4
- 230000001413 cellular effect Effects 0.000 claims description 4
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims description 3
- 108010076667 Caspases Proteins 0.000 claims description 3
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims description 3
- 101000704221 Homo sapiens Serine palmitoyltransferase small subunit A Proteins 0.000 claims description 3
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 claims description 3
- 102100026326 Putative transcription factor Ovo-like 1 Human genes 0.000 claims description 3
- 102100031872 Serine palmitoyltransferase small subunit A Human genes 0.000 claims description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 3
- 102000003566 TRPV1 Human genes 0.000 claims description 3
- 210000003608 fece Anatomy 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000005070 sampling Methods 0.000 claims description 3
- 210000004927 skin cell Anatomy 0.000 claims description 3
- 230000003827 upregulation Effects 0.000 claims description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 2
- 102000011727 Caspases Human genes 0.000 claims description 2
- 102100030332 Homeobox protein Mohawk Human genes 0.000 claims description 2
- 101000990997 Homo sapiens Homeobox protein Mohawk Proteins 0.000 claims description 2
- 101001121371 Homo sapiens Putative transcription factor Ovo-like 1 Proteins 0.000 claims description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 2
- 230000002500 effect on skin Effects 0.000 claims description 2
- 238000002955 isolation Methods 0.000 claims description 2
- 239000006166 lysate Substances 0.000 claims description 2
- 230000006654 negative regulation of apoptotic process Effects 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 229940127557 pharmaceutical product Drugs 0.000 claims description 2
- 239000000284 extract Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002516 radical scavenger Substances 0.000 claims 1
- 238000002474 experimental method Methods 0.000 abstract description 14
- 230000006870 function Effects 0.000 abstract description 11
- 230000001737 promoting effect Effects 0.000 abstract description 10
- 238000004321 preservation Methods 0.000 abstract description 6
- 230000032683 aging Effects 0.000 abstract description 5
- 244000005700 microbiome Species 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- 210000003205 muscle Anatomy 0.000 abstract description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 14
- 230000002757 inflammatory effect Effects 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- 238000001514 detection method Methods 0.000 description 13
- 241000894006 Bacteria Species 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 238000003753 real-time PCR Methods 0.000 description 8
- 230000003078 antioxidant effect Effects 0.000 description 7
- 229910002092 carbon dioxide Inorganic materials 0.000 description 7
- 239000001569 carbon dioxide Substances 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 210000002510 keratinocyte Anatomy 0.000 description 7
- 239000003963 antioxidant agent Substances 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 210000000434 stratum corneum Anatomy 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 230000003064 anti-oxidating effect Effects 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 238000004364 calculation method Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000009759 skin aging Effects 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 108010024636 Glutathione Proteins 0.000 description 4
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 4
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 4
- -1 hydroxyl radicals Chemical class 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 3
- 102100028314 Filaggrin Human genes 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 102100023913 Involucrin Human genes 0.000 description 3
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 108010029483 alpha 1 Chain Collagen Type I Proteins 0.000 description 3
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 238000002247 constant time method Methods 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 101150084750 1 gene Proteins 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 2
- 102100027308 Apoptosis regulator BAX Human genes 0.000 description 2
- 229920000832 Cutin Polymers 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102100030013 Endoribonuclease Human genes 0.000 description 2
- 101710199605 Endoribonuclease Proteins 0.000 description 2
- 238000003794 Gram staining Methods 0.000 description 2
- 101001013150 Homo sapiens Interstitial collagenase Proteins 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 102100031784 Loricrin Human genes 0.000 description 2
- 230000002292 Radical scavenging effect Effects 0.000 description 2
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000007760 free radical scavenging Effects 0.000 description 2
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 102100033601 Collagen alpha-1(I) chain Human genes 0.000 description 1
- 102000005927 Cysteine Proteases Human genes 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 229920002444 Exopolysaccharide Polymers 0.000 description 1
- 101150063233 FLG gene Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 108010020382 Hepatocyte Nuclear Factor 1-alpha Proteins 0.000 description 1
- 102100022057 Hepatocyte nuclear factor 1-alpha Human genes 0.000 description 1
- 101150027725 IVL gene Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 108050006599 Metalloproteinase inhibitor 1 Proteins 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101150012407 OVOL1 gene Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108010024814 Serine C-palmitoyltransferase Proteins 0.000 description 1
- 206010041303 Solar dermatitis Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 108700000707 bcl-2-Associated X Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000000736 corneocyte Anatomy 0.000 description 1
- 238000003235 crystal violet staining Methods 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 210000005002 female reproductive tract Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 208000001875 irritant dermatitis Diseases 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000006676 mitochondrial damage Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 108700026241 pX Genes Proteins 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- YQUVCSBJEUQKSH-UHFFFAOYSA-N protochatechuic acid Natural products OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 108020000318 saccharopine dehydrogenase Proteins 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- WKOLLVMJNQIZCI-UHFFFAOYSA-N vanillic acid Chemical compound COC1=CC(C(O)=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-N 0.000 description 1
- TUUBOHWZSQXCSW-UHFFFAOYSA-N vanillic acid Natural products COC1=CC(O)=CC(C(O)=O)=C1 TUUBOHWZSQXCSW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/02—Separating microorganisms from their culture media
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Birds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明公开了一株詹氏乳杆菌及其应用,涉及微生物技术领域。本发明公开的詹氏乳杆菌(Lactobacillus.jensenii),该菌株被命名为GforU‑13,已于2022年5月23日保藏在中国典型培养物保藏中心,其保藏编号为CCTCC No:M2022693的詹氏乳杆菌。实验表明,GforU‑13具有修护皮肤屏障、抗衰老、促细胞增殖、抗炎、抗自由基、改善敏感肌的功能,可用于制备食品、药品、化妆品等。
Description
技术领域
本发明属于微生物的技术领域,具体地涉及一株詹氏乳杆菌及其应用。
背景技术
皮肤是人体内最大的器官,总重量大约占个体体重的16%,一方面维持机体稳定,另一方面也是抵御外界不良因素侵扰的第一道防线。有研究表明,如果外界环境导致皮肤屏障中的相关基因异常,就会诱发皮肤疾病。
皮肤屏障是由角质层的表皮形成细胞和角质间的脂质形成的结构性的屏障。皮肤屏障防止人体过多水分释放,并防止如化学物质或微生物的有害物质进入我们的身体。组成死亡的角质细胞的表面的角质细胞外皮在细胞间脂质的稳定性中起重要作用。皮肤屏障受损将引起皮肤干燥、皮肤老化、色素沉着异位性皮炎、湿疹、银屑病、鱼鳞病、日旋光性皮炎等皮肤敏感、刺激性皮炎、激素依赖性皮炎等皮肤油腻、皮脂溢出性疾病,如痤疮、酒糟鼻、脂溢性皮炎。
角质间结构性脂质神经酰胺,在基底层向角质分化过程中含量逐渐增加,到达角质层排至细胞间隙,构成防止水分丢失的屏障。角质细胞内含水量高,随着细胞向上代谢分化,角质细胞形状会逐渐变成扁平状,且细胞核及胞器开始退化萎缩,并在角质层形成不具细胞核与胞器的死细胞。角质层本身的亲水、屏障功能,以及角质层中所含有的天然保湿因子即氨基酸类,乳酸盐及糖类等作用,使得角质层通常含有10%~30%的水分,这种环境成为了皮肤自身微生物菌落生长的摇篮。但随着年龄的增长,角质层的含水量会逐渐减少,当水分含量低于10%的时候,就会引起皮肤的各种问题。
皮肤衰老,包括由空气污染、吸烟、营养不良和紫外线(UV)等环境因素引起的外在衰老和由时间变化引起的内在衰老。其典型特征是皮肤变薄、产生细纹,这可能是由于细胞增殖减少以及随着年龄增长引起的真皮成分发生显着变化导致的。细胞外基质成分(胶原蛋白、弹性蛋白、糖胺聚糖等)随着皮肤衰老而显着减少。此外,伴随增龄,多种因素如线粒体损伤、炎症反应等产生的活性氧增加,同时,与年龄相关的细胞修复能力下降,使得氧化应激增加,老化受损细胞无法及时清除,从而导致了皮肤衰老。
詹氏乳杆菌作为一类乳酸杆菌是定殖在女性生殖道中最常见和最重要的有益菌群,在维持女性***健康中发挥着关键作用。其在妇科炎症方面的作用已被广泛报道,而在皮肤上的作用却鲜为人知。益生菌用在化妆品上,可平衡皮肤表皮菌群,修复皮肤屏障,抵御皮肤衰老,有效增加肌肤对营养物质的吸收,增强免疫力。
敏感肌通常是由于皮肤细胞受损而使皮肤免疫力下降,角质层变薄导致皮肤滋润度不够,最终导致肌肤的屏障功能过于薄弱,无法抵御外界刺激,从而易于产生泛红、发热、瘙痒、刺痛等不适现象的产生。因此,提供一种利用微生态技术开发的益生菌相关产品,具有重要的现实意义。
发明内容
有鉴于此,本发明的目的是提供了一株詹氏乳杆菌及其应用。
本发明提供了詹氏乳杆菌(Lactobacillus.jensenii),该菌株被命名为GforU-13,已于2022年5月23日保藏在中国典型培养物保藏中心(简称CCTCC,地址为:武汉市武昌区八一路299号,武汉大学,邮编430072),其保藏编号为CCTCC No:M 2022693的詹氏乳杆菌。
较佳地,上述詹氏乳杆菌采用如下分离方法制得:
采样于健康八岁女童粪便,将该样品适当处理后于生理盐水中震荡混匀,取上清划线于MRS固体平板,37℃恒温培养48h后,挑取白色菌落反复接种筛选,直至得到均匀的单个菌落,命名为GforU-13。
较佳地,上述詹氏乳杆菌在革兰氏染色镜检下菌株GforU-13革兰氏染色阳性,显微镜下呈杆状;在MRS平板上生长,可形成白色、表面光滑圆润不透明圆形小菌落,边缘整齐;在MRS液体培养基中呈均匀浑浊生长,久置菌体呈白色沉淀。
本发明的另一目的是提供了上述詹氏乳杆菌在制备改善肌肤状况的产品中的应用。
较佳地,所述改善肌肤状况包括修护皮肤屏障、抗衰老、促细胞增殖、抗炎、抗自由基中的至少一种。
一些实施方案中,所述修复皮肤屏障包括修复皮肤细胞和/或上调屏障修护相关基因的表达;所述屏障修护相关基因包括FLG、IVL、OVOL1和/或LOR。
一些实施方案中,所述抗衰老为上调细胞外基质相关基因的表达;所述细胞外基质相关基因包括LN、MKX、SPTSSA、TIMP1、COL1A1中的至少一种。
一些实施方案中,所述抗衰老为下调细胞炎症相关因子基因的表达;所述细胞炎症相关因子基因包括TNF-α和/或IL-6。
一些实施方案中,所述抗衰老为下调细胞凋亡和上调抑制细胞凋亡相关基因的表达;所述细胞凋亡相关基因包括BAX和/或Caspase家族的表达,所述抑制细胞凋亡相关基因包括BCL-2。
一些实施方案中,所述抗衰老为下调降解细胞外基质相关基因的表达;所述降解细胞外基质相关基因包括P38MAPK和/或MMP家族的表达。
一些实施方案中,所述促细胞增殖为促进皮肤成纤维细胞增殖。
一些实施方案中,所述抗炎为下调细胞炎症相关因子基因的表达;所述细胞炎症相关因子基因包括IL-8和/或TRPV1。
一些实施方案中,所述抗自由基为对羟自由基和/或ABTS自由基的清除作用。
一些实施方案中,所述产品为食品、药品或化妆品。
一些实施方案中,所述产品中的詹氏乳杆菌包括如下所示的一种或者两种:
(1)詹氏乳杆菌的活菌和/或灭活菌;
(2)詹氏乳杆菌的培养物或代谢物。
本发明公开的詹氏乳杆菌(Lactobacillus.jensenii)GforU-13,其保藏编号为CCTCC No:M 2022693。实验表明,GforU-13具有修护皮肤屏障、抗衰老、促细胞增殖、抗炎、抗自由基的功能,可用于制备食品、药品、化妆品等。
生物保藏说明
詹氏乳杆菌(Lactobacillus.jensenii)GforU-13,于2022年5月23日保藏在中国典型培养物保藏中心(简称CCTCC,地址为:武汉市武昌区八一路299号,武汉大学,邮编430072),其保藏编号为CCTCC No:M 2022693。
具体实施方式
本发明提供了詹氏乳杆菌及其应用。本领域技术人员可以借鉴本文内容,适当改进工艺参数实现。特别需要指出的是,所有类似的替换和改动对本领域技术人员来说是显而易见的,它们都被视为包括在本发明。本发明的方法及应用已经通过较佳实施例进行了描述,相关人员明显能在不脱离本发明内容、精神和范围内对本文的方法和应用进行改动或适当变更与组合,来实现和应用本发明技术。
本发明的詹氏乳杆菌菌株GforU-13,筛选自健康八岁女童粪便,经16S rDNA鉴定为詹氏乳杆菌(Lactobacillus.jensenii)。该菌株革兰氏阳性,显微镜下呈杆状;在MRS平板上生长,可形成表面光滑不透明的圆形菌落,白色,边缘整齐;在MRS液体培养基中呈均匀浑浊生长,久置菌体呈白色沉淀,最适生长温度37℃。
詹氏乳杆菌(Lactobacillus.jensenii)GforU-13,于2022年5月23日保藏在中国典型培养物保藏中心(简称CCTCC,地址为:武汉市武昌区八一路299号,武汉大学,邮编430072),其保藏编号为CCTCC No:M 2022693。
进一步,本发明提供的詹氏乳杆菌GforU-13在本发明所述应用的产品中,存在形式是活的或死的或经间歇灭菌的,或为细菌产物的形式或为上清液形式或衍生物形式,所述衍生物形式优选地选自:代谢产物、代谢生物产物、益生素、细胞壁及其成分、胞外多糖,和含有免疫原性成分的化合物,优选地选自:上清液、灭活菌体。
体外细胞实验表明,本发明的詹氏乳杆菌GforU-13具有上调皮肤屏障修护相关因子丝聚合蛋白(filaggrin)FLG、外皮蛋白(Involucrin)IVL、兜甲蛋白(loricrin)LOR、Ovo样转录因子1(Ovo Like Transcriptional Repressor1)OVOL1表达的作用,基因表达量上调1.32倍~4.68倍。
体外细胞实验表明,本发明的詹氏乳杆菌GforU-13具有上调HaCaT角质细胞外基质相关的组织金属蛋白酶抑制物1基因TIMP1和Ⅰ型胶原α1链基因COL1A1,基因相对表达量上调1.30倍~1.51倍、降解细胞外基质相关的基质金属蛋白酶家族基因MMP1和P38丝氨酸/苏氨酸蛋白激酶P38MAPK基因、炎症因子肿瘤坏死因子-α基因TNF-α和白介素6基因IL-6,基因相对表达量下调0.14倍~0.79倍。
体外细胞实验表明,本发明的詹氏乳杆菌GforU-13具有促进HFF人成纤维细胞增殖的作用,增殖率35.16%~47.01%。
体外细胞实验表明,本发明的詹氏乳杆菌GforU-13具有上调HFF人成纤维细胞外基质相关的层粘连蛋白基因LN、丝氨酸棕榈酰转移酶基因SPTSSA和莫霍克蛋白基因MKX,抗氧化相关的去乙酰化蛋白1基因SIRT-3,以及抑制细胞凋亡相关B淋巴细胞瘤-2基因(B-cell lymphoma-2)BCL-2表达的作用,基因相对表达量上调1.10倍~5.40倍;具有下调降解细胞外基质相关的基质金属蛋白酶家族基因MMP的表达和P38丝氨酸/苏氨酸蛋白激酶P38MAPK,细胞凋亡相关的BCL2-Associated X蛋白基因BAX和半胱氨酸蛋白酶家族基因Caspase,炎症因子白介素6基因IL-6的表达,相对表达量下调0.18倍~0.88倍。
体外细胞实验表明,本发明的詹氏乳杆菌GforU-13具有下调LPS诱导的HaCaT细胞炎症相关因子白介素8基因IL-8和香草酸瞬时受体亚型1基因TRPV1表达的作用,基因表达量下调0.14倍~0.54倍。
体外细胞实验表明,本发明的詹氏乳杆菌GforU-13具有清除羟自由基和ABTS自由基的功能,自由基清除率7.41%~34.83%。
体外细胞实验表明,本发明的詹氏乳杆菌GforU-13具有抗氧化的功能,总抗氧化能力为1.40μmol/ml~1.53μmol/ml,还原型谷胱甘肽含量为48.81μmol/ml~60.71ug/ml。
本发明采用的试材皆为普通市售品,均可市售购买得到,下面结合实施例,进一步阐述本发明:
实施例1:GforU-13的分离
采样于健康八岁女童粪便,将该样品适当处理后于生理盐水中震荡混匀,取上清划线于MRS固体平板,37℃恒温培养48h后,挑取白色菌落反复接种筛选,直至得到均匀的单个菌落,命名为GforU-13。
革兰氏染色镜检:菌株GforU-13为革兰氏染色阳性,显微镜下呈杆状;在MRS平板上生长,可形成白色、表面光滑圆润不透明圆形小菌落,边缘整齐;在MRS液体培养基中呈均匀浑浊生长,久置菌体呈白色沉淀。
实施例2:GforU-13的核酸鉴定
1、16S rDNA基因序列分析:
挑取单菌落置MRS液体培养基中,37℃培养过夜后,12000转离心1min收集菌体,按照DNA提取试剂盒步骤进行操作。引物采用细菌通用引物27F,1492R,PCR扩增体系为50μL体系,95℃预变性5min;94℃ 15s,57℃ 15s,72℃ 40s,35个循环;72℃延伸10min。
2、结果
PCR产物测序结果与GenBank中已发表的标准序列进行同源性比较(BLASTN)后得出GforU-13菌株为詹氏乳杆菌(Lactobacillus.jensenii)。
实施例3:GforU-13促进HaCaT屏障修护相关基因表达实验
1、GforU-13上清液和灭活菌体制备:
挑取詹氏乳杆菌GforU-13单菌落于MRS液体培养基,37℃培养箱静置培养16~18h,酶标仪检测并以PBS稀释调整OD600=0.2,121℃,30min高压灭活,12000转离心2min,经0.22μm滤膜过滤为上清液。离心沉淀以适量PBS重悬,稀释调整OD600=0.2,为灭活菌体。
2、促进HaCaT屏障修护相关基因表达实验
接种人永生化角质形成细胞HaCaT(2ml/孔,内含5×105细胞)至6孔板,5%二氧化碳培养箱37℃过夜培养至细胞贴壁。分别加入上清液5%(V/V),灭活菌体10%(V/V),对照组分别以等体积PBS替代上清液/灭活菌体,培养24h后,加入裂解液,提取细胞总RNA,检测RNA浓度及纯度后反转录为cDNA,以GAPDH为内参基因,采用实时qPCR检测FLG、IVL、OVOL1和LOR基因的表达。分别以等体积PBS处理组为对照(基因相对表达倍数F=1),利用2-ΔΔCT法计算各样品F值。
公式:F=2-ΔΔCT,其中:
△CT实验=CT实验-CT内参(实验);
△CT对照=CT对照-CT内参(对照);
△△CT=△CT实验-△CT对照。
结果见下表:
结果显示GforU-13上清液具有促进皮肤屏障修护的作用。
实施例4:GforU-13调节光老化HaCaT角质细胞外基质/炎症因子相关基因表达实验
1、GforU-13上清液及灭活菌体制备:
制备方法参照实施例3。
2、HaCaT细胞制备及紫外线损伤
将HaCaT细胞消化后以0.5ml/孔(内含2×105细胞)接种至24孔板,5%二氧化碳培养箱37℃培养过夜。对孔内细胞进行总剂量为2J/cm2的紫外线UVB照射损伤。
3、GforU-13添加
将上清液5%(V/V)、灭活菌体10%(V/V)分别加入刺激过的HaCaT细胞(对照组分别以等体积PBS替代上清液/灭活菌体)。每组3平行,37℃培养过夜。
4、qPCR法检测降解细胞外基质/炎症因子基因相对表达倍数
将上述细胞弃去培养基后,加入裂解液,提取细胞总RNA,检测RNA浓度及纯度后反转录为cDNA,以GAPDH为内参基因,采用实时qPCR检测细胞外基质相关基因TIMP1、COL1A1,细胞外基质降解相关基因MMP1、P38,炎症因子相关基因TNF-α、IL-6的表达。以对照组基因相对表达倍数F=1,利用2-ΔΔCT法计算各样品F值。
上清液下调细胞外基质降解基因和炎症因子基因,结果见下表:
灭活菌体上调细胞外基质基因,下调细胞外基质降解基因和炎症因子基因,结果见下表:
结果显示加入GforU-13具有促进HaCaT角质细胞外基质合成、减少细胞外基质降解并减少炎症因子的抗衰老作用。
实施例5:GforU-13促进HFF细胞的增殖
1、GforU-13上清液及灭活菌体制备:
制备方法参照实施例3。
2、HFF细胞制备及GforU-13添加
将DMEM培养的HFF细胞消化后以0.5ml/孔(每孔含1.5×105细胞)接种至24孔板,5%二氧化碳培养箱37℃培养过夜。将10%(V/V)上清液和灭活菌体分别加入HFF细胞(对照组以等体积PBS替代)。每组3平行,37℃培养过夜。
3、HFF细胞转接及染色计数
将24孔板内的HFF细胞计数后适当稀释,以2ml/孔(每孔含2.0×103细胞)转接6孔板,每组3平行,5%二氧化碳培养箱37℃培养7天~10天。对孔内细胞用多聚甲醛固定后结晶紫染色计数。根据公式计算细胞增殖率。
计算公式及结果如下表:
结果显示添加GforU-13具有促进HFF细胞增殖的作用。
实施例6:GforU-13调节氧化损伤人成纤维细胞外基质/细胞凋亡/抗氧化/炎症因子相关基因表达实验
1、GforU-13上清液及灭活菌体制备:
制备方法参照实施例3。
2、HFF人成纤维细胞制备及H2O2诱导氧化损伤
将DMEM培养的HFF细胞消化后以0.5ml/孔(内含2×105细胞)接种至24孔板,5%二氧化碳培养箱37℃培养过夜。每孔加入终浓度为200μM的H2O2进行刺激,37℃静置1h。
3、GforU-13添加
将上清液5%(V/V)、灭活菌体10%(V/V)分别加入刺激过的HFF细胞(对照组分别以等体积PBS替代上清液/灭活菌体)。每组3平行,37℃培养过夜。
4、qPCR法检测细胞外基质/细胞凋亡/抗氧化/炎症因子相关基因相对表达倍数
将上述细胞弃去培养基后,加入裂解液,提取细胞总RNA,检测RNA浓度及纯度后反转录为cDNA,以GAPDH为内参基因,采用实时qPCR检测细胞外基质、抗氧化、细胞凋亡、炎症因子相关基因的表达。以对照组基因相对表达倍数F=1,利用2-ΔΔCT法计算各样品F值。
上清液调节HFF人成纤维细胞相关基因结果见下表:
灭活菌体调节HFF人成纤维细胞相关基因结果见下表:
结果显示加入GforU-13具有促进HFF人成纤维细胞外基质合成、减少细胞外基质降解、减少细胞凋亡以清除老化细胞、增加抗氧化能力以及减少炎症因子的抗衰老作用。
实施例7:GforU-13下调HaCaT细胞炎症因子相关基因的表达
1、GforU-13上清液制备:
制备方法参照实施例3。
2、HaCaT细胞制备
将HaCaT细胞消化后以0.5ml/孔(内含2×105细胞)接种至24孔板,5%二氧化碳培养箱37℃培养过夜。
3、GforU-13上清液添加及LPS刺激
将GforU-13上清液以5%(V/V)加入培养过夜的HaCaT细胞中,以等体积PBS为对照组,2h后添加0.5ml浓度为0.2μg/ml的LPS溶液,诱导细胞发炎,每组3平行,5%二氧化碳培养箱37℃培养20h。
4、qPCR法检测细胞炎症因子基因相对表达倍数
将上述细胞弃去培养基后,加入裂解液,提取细胞总RNA,检测RNA浓度及纯度后反转录为cDNA,以GAPDH为内参基因,采用实时qPCR检测IL-8和TRPV1基因的表达。以等体积PBS处理组为对照(基因相对表达倍数F=1),利用2-ΔΔCT法计算各样品F值。
结果见下表:
结果显示GforU-13能够下调LPS诱导HaCaT细胞炎症因子相关基因表达量至0.15倍~0.37倍。因此,GforU-13具有抗炎作用。
实施例8:GforU-13清除自由基的作用
1、GforU-13上清液制备:
挑取詹氏乳杆菌GforU-13单菌落于MRS液体培养基,37℃培养箱静置培养16h~18h,酶标仪检测并以MRS液体培养基稀释调整OD600=2.0,121℃,30min高压灭活,12000转离心2min,上清液经0.22μm滤膜过滤为上清液。
2、GforU-13上清液羟自由基清除能力检测
试剂配制和检测方法按照索莱宝羟自由基清除能力检测试剂盒说明书进行。测定各样品536nm吸亮度,求平均值并计算各样品清除率。
计算公式及结果如下表:
3、GforU-13上清液ABTS自由基清除能力检测
试剂配制和检测方法按照索莱宝ABTS自由基清除能力检测试剂盒说明书进行。测定各样品405nm吸亮度,求平均值并计算各样品清除率。
计算公式及结果如下表:
结果显示GforU-13具有清除羟自由基和ABTS自由基的作用,自由基清除率7.41%~34.83%。
实施例9:GforU-13抗氧化作用
1、GforU-13上清液制备:
制备方法参照实施例8。
2、GforU-13上清液总抗氧化氧化能力检测
试剂配制和检测方法按照索莱宝总抗氧化能力检测试剂盒说明书进行。测定各样品593nm处吸亮度,求平均值并计算各样品清除率,计算公式为总抗氧化能力(μmol/ml)=X×V反总÷V样,A测-A空白=11.232x+0.0197,V反总:反应总体积,0.204ml,V样:反应中样本体积,0.006ml。
计算公式及结果如下表:
3、GforU-13上清液还原型谷胱甘肽含量检测
试剂配制和检测方法按照索莱宝还原型谷胱甘肽检测试剂盒说明书进行。测定各样品412nm处的吸亮度,求平均值并计算各样品清除率。
计算公式及结果如下表:
结果显示GforU-13具有抗氧化的作用,总抗氧化能力为1.40μmol/ml~1.53μmol/ml,还原型谷胱甘肽含量为48.81μg/ml~60.71μg/ml。
以上仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (15)
1.一株詹氏乳杆菌(Lactobacillus.jensenii),该菌株被命名为GforU-13,已于2022年5月23日保藏在中国典型培养物保藏中心,其保藏编号为CCTCC No:M 2022693的詹氏乳杆菌。
2.根据权利要求1所述的詹氏乳杆菌,其特征在于,采用如下分离方法制得:
采样于健康八岁女童粪便,将该样品适当处理后于生理盐水中震荡混匀,取上清划线于MRS固体平板,37℃恒温培养48h后,挑取白色菌落反复接种筛选,直至得到均匀的单个菌落,命名为GforU-13。
3.根据权利要求1所述的詹氏乳杆菌,其特征在于,在革兰氏染色镜检下菌株GforU-13革兰氏染色阳性,显微镜下呈杆状;在MRS平板上生长,可形成白色、表面光滑圆润不透明圆形小菌落,边缘整齐;在MRS液体培养基中呈均匀浑浊生长,久置菌体呈白色沉淀。
4.权利要求1~3任一项所述的詹氏乳杆菌在制备改善肌肤状况的产品中的应用。
5.根据权利要求4所述的应用,其特征在于,所述改善肌肤状况包括修护皮肤屏障、抗衰老、促细胞增殖、抗炎、抗自由基中的至少一种。
6.根据权利要求5所述的应用,其特征在于,所述修复皮肤屏障为修复皮肤细胞和/或上调屏障修护相关基因的表达;所述屏障修护相关基因包括FLG、IVL、OVOL1和/或LOR。
7.根据权利要求5所述的应用,其特征在于,所述抗衰老为上调细胞外基质相关基因的表达;所述细胞外基质相关基因包括LN、MKX、SPTSSA、TIMP1、COL1A1中的至少一种。
8.根据权利要求5所述的应用,其特征在于,所述抗衰老为下调细胞炎症相关因子基因的表达;所述细胞炎症相关因子基因包括TNF-α和/或IL-6。
9.根据权利要求5所述的应用,其特征在于,所述抗衰老为下调细胞凋亡和上调抑制细胞凋亡相关基因的表达;所述细胞凋亡相关基因包括BAX和/或Caspase家族的表达,所述抑制细胞凋亡相关基因包括BCL-2。
10.根据权利要求5所述的应用,其特征在于,所述抗衰老为下调降解细胞外基质相关基因的表达;所述降解细胞外基质相关基因包括P38MAPK和/或MMP家族的表达。
11.根据权利要求5所述的应用,其特征在于,所述促细胞增殖为促进皮肤成纤维细胞增殖。
12.根据权利要求5所述的应用,其特征在于,所述抗炎为下调细胞炎症相关因子基因的表达;所述细胞炎症相关因子基因包括IL-8和/或TRPV1。
13.根据权利要求5所述的应用,其特征在于,所述抗自由基为对羟自由基和/或ABTS自由基的清除作用。
14.根据权利要求4~12任一项所述的应用,其特征在于,所述产品为食品、药品或化妆品。
15.根据权利要求14所述的应用,其特征在于,所述产品中的詹氏乳杆菌包括如下所示的一种或者两种:
(1)詹氏乳杆菌的活菌和/或灭活菌;
(2)詹氏乳杆菌的培养物、裂解物和/或提取物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210932906.1A CN115261273A (zh) | 2022-08-04 | 2022-08-04 | 一株詹氏乳杆菌及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210932906.1A CN115261273A (zh) | 2022-08-04 | 2022-08-04 | 一株詹氏乳杆菌及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115261273A true CN115261273A (zh) | 2022-11-01 |
Family
ID=83748182
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210932906.1A Withdrawn CN115261273A (zh) | 2022-08-04 | 2022-08-04 | 一株詹氏乳杆菌及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115261273A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115820516A (zh) * | 2023-01-10 | 2023-03-21 | 廖梅香 | 一株枯草芽孢杆菌及其应用 |
CN117165477A (zh) * | 2023-09-04 | 2023-12-05 | 广西爱生生命科技有限公司 | 一种延寿抗衰的卷曲乳杆菌a21013和a21033及其应用 |
-
2022
- 2022-08-04 CN CN202210932906.1A patent/CN115261273A/zh not_active Withdrawn
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115820516A (zh) * | 2023-01-10 | 2023-03-21 | 廖梅香 | 一株枯草芽孢杆菌及其应用 |
CN117165477A (zh) * | 2023-09-04 | 2023-12-05 | 广西爱生生命科技有限公司 | 一种延寿抗衰的卷曲乳杆菌a21013和a21033及其应用 |
CN117165477B (zh) * | 2023-09-04 | 2024-03-29 | 广西爱生生命科技有限公司 | 一种延寿抗衰的卷曲乳杆菌a21013和a21033及其应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN115261273A (zh) | 一株詹氏乳杆菌及其应用 | |
CN114081901B (zh) | 一种益生菌组合物、制备方法及其应用 | |
CN115094011A (zh) | 一株加氏乳杆菌及其应用 | |
CN114634899B (zh) | 发酵乳杆菌及其应用 | |
CN115058373B (zh) | 清酒乳杆菌及其应用 | |
CN115044519B (zh) | 解淀粉乳杆菌及其应用 | |
CN115678814A (zh) | 一种唾液乳杆菌及其应用 | |
CN115197856B (zh) | 一种蛹虫草菌株及其应用 | |
CN115491334A (zh) | 一株鼠李糖乳杆菌及其应用 | |
CN115505550A (zh) | 一株副干酪乳杆菌及其应用 | |
CN116555070A (zh) | 一株双歧双歧杆菌及其应用 | |
CN115584333A (zh) | 罗伊氏乳杆菌及其应用 | |
CN115806914A (zh) | 一种植物乳杆菌及其应用 | |
CN114717161A (zh) | 发酵乳杆菌及其应用 | |
CN114711429A (zh) | 一株具有增强骨健康作用的罗伊氏乳杆菌及其应用 | |
CN116286415B (zh) | 一株橙红色掷孢酵母及其应用 | |
CN116355770B (zh) | 一种汉逊德巴利酵母及其应用 | |
CN115287204B (zh) | 一种马克斯克鲁维酵母菌株及其应用 | |
CN115927119B (zh) | 一种简单芽孢杆菌及其应用 | |
CN116445306B (zh) | 粟酒裂殖酵母及其改善皮肤状况的应用 | |
CN115678807B (zh) | 一种长双歧杆菌及其应用 | |
CN115197883A (zh) | 解淀粉乳杆菌及其皮肤修复抗衰老应用 | |
CN115141783A (zh) | 清酒乳杆菌清酒亚种及其皮肤修复保湿抗衰的应用 | |
CN116478875A (zh) | 一株蜡状芽孢杆菌及其应用 | |
CN115786208A (zh) | 一种短乳杆菌及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20221101 |